Olivier Ledanois
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT).
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: January 30, 2026
Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization Level.
Journal: The journal of allergy and clinical immunology. In practice
Published: December 24, 2025
Comparative effectiveness of biologics in lung function improvement among patients with severe asthma: a real-world study.
Journal: Respiratory research
Published: October 24, 2025
The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled asthma and type 2 inflammation.
Journal: The journal of allergy and clinical immunology. Global
Published: October 20, 2025
Improved asthma outcomes with dupilumab plus medium-dose inhaled corticosteroids vs placebo plus high-dose inhaled corticosteroids.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: September 04, 2025
Dupilumab sustains efficacy despite LABA and ICS withdrawal in patients with asthma: A post hoc analysis.
Journal: The journal of allergy and clinical immunology. In practice
Published: July 23, 2025
Long-term Efficacy of Dupilumab Versus Tezepelumab in Asthma: A Matching-Adjusted Indirect Comparison.
Journal: The journal of allergy and clinical immunology. In practice
Published: July 21, 2025
Burden of disease and unmet clinical needs in pediatric patients with asthma: real-world experience from the United States and five European countries.
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: June 09, 2025
Dupilumab efficacy by disease severity in pediatric type 2 asthma.
Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Published: March 28, 2025
Dupilumab Plus Medium-Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High-Dose ICS in Children With Uncontrolled Moderate-to-Severe Type 2 Asthma.
Journal: Pediatric pulmonology
Published: December 23, 2024
Last Updated: 09/26/2026